Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody

Table 1 Baseline characteristics n (%)

Characteristics	Value
Patients (n)	18
Female	13 (72)
Age at diagnosis in yr, median (range)	7.8 (2.9-15.3)
Age on ADA start in yr, median (range)	14.4 (5.3-19.1)
Age at diagnosis < 10 yr	12 (67)
Age at diagnosis 10-17 yr	6 (33)
Disease location according to Paris classification
L1 small intestine	2 (11)
L2 colon	12 (67)
L3 small intestine and colon	10 (55)
L4a upper gastrointestinal tract	9 (50)
P perianal disease	2 (11)
Granuloma	4 (22)
IBD-related medications at start of adalimumab
Corticosteroids	11 (61)
5-aminosalicylic acid	14 (78)
Immunomodulatory agents
Azathioprine/6-mercaptopurine	4 (22)
Methotrexate	5 (28)
Cyclosporin/tacrolimus	2 (11)
Biologics
Prior infliximab use	17 (94)
Number of children on IFX at start of ADA	14 (78)
Duration of prior infliximab use (mo), median (range)	1 (0.5-2)
Number of infliximab infusion, median (range)	11 (7-23)
Allergic reactions to IFX	1 (6)
Calcium/vitamin D supplements	11 (61)

ADA: Adalimumab; IFX: Infliximab; IBD: Inflammatory bowel disease.